Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21222072 | 1.00 | BACE1 (0.36) | BACE1AKR1C3AKR1C1S1PR5MKNK1 | |
| SCHEMBL22614223 | 1.00 | BACE1 (0.36) | BACE1AKR1C3AKR1C1S1PR5MKNK1 | |
| SCHEMBL5831941 | 0.98 | BACE1 (0.36) | BACE1AKR1C3AKR1C1S1PR5MKNK1 | |
| SCHEMBL5831935 | 0.98 | BACE1 (0.36) | BACE1AKR1C3AKR1C1S1PR5MKNK1 | |
| SCHEMBL6951863 | 0.93 | BACE1 (0.34) | BACE1AKR1C3AKR1C1S1PR5MKNK1 | |
| SCHEMBL22160094 | 0.90 | AKR1C3 (0.42) | BACE1AKR1C3AKR1C1S1PR5 | |
| SCHEMBL30315459 | 0.90 | AKR1C3 (0.42) | BACE1AKR1C3AKR1C1S1PR5 | |
| SCHEMBL871189 | 0.90 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL31414305 | 0.90 | BACE1 (0.36) | BACE1HSD11B1HSD11B2CYP3A4HTT | |
| SCHEMBL25520994 | 0.90 | BACE1 (0.36) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119997953-A | Alpha protein kinase 1 inhibitors for the treatment of kidney diseases and kidney related diseases | 上海药苑生物科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543443-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025082485-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025076632-A1 | COMPOUNDS AND USES THEREOF | FIBROCOR THERAPEUTICS INC. (CA) | 2025-04-17 | — | — | WO | disclosed |
| CN-114874209-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118103045-A | Alpha protein kinase 1 inhibitors for the treatment of kawasaki disease | 上海药苑生物科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-114828959-B | 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114206848-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3962906-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| WO-2021124172-A1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223538-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| CN-111148746-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-05-12 | — | — | CN | disclosed |
| CN-110809574-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | BACE1 3266/4885AKR1C3 318/4885AKR1C1 260/4885 |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | BACE1 1349/4885AKR1C3 705/4885AKR1C1 943/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | BACE1 3266/4885AKR1C3 318/4885AKR1C1 260/4885 |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | BACE1 3979/4885AKR1C3 2127/4885AKR1C1 1954/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | BACE1 3336/4885AKR1C3 1585/4885AKR1C1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.